BlueOcean Ventures
BlueOcean Ventures is a venture capital firm based in Geneva, Switzerland, with an additional office in Zurich. Established in 2008, the firm specializes in seed and early-stage investments, primarily targeting high technology companies in sectors such as medical devices, diagnostics, information and communication technology (ICT), medtech, environmental engineering, and life sciences. BlueOcean Ventures focuses its investments on companies located in Switzerland and Europe, with an interest in neighboring countries. The firm typically invests between 300,000 and 600,000 Swiss Francs in initial funding rounds, with total investments reaching up to 1.5 million Swiss Francs per company. It looks for companies valued between 3 million and 10 million Swiss Francs at the first round and often seeks a board seat in its portfolio companies. Additionally, BlueOcean Ventures provides operational and advisory support to entrepreneurs, assisting in areas such as management, negotiation, and divestment strategies. The investment horizon for the firm can extend up to ten years.
MIKAJAKI SA designs and develops automated multi patient ocular diagnostics platform. The company was founded in 2018 and is based in Plan-les-Ouates, Switzerland.
Cyanoguard AG is a chemical technology company specialised in the development of novel toxin detection methods to improve environmental monitoring, food safety and health care in remote settings and locations. Its innovative technology enables fast and safe cyanide detection in food, waste water and other samples. Its method is selective and requires no special training and/or equipment. Equipped with the latest research, and with over six years of close collaboration with leading industry partners, the company is dedicated to resolve today's cyanide issues, offering fast and safe toxin detection in any setting at any time.
99RetailStreet is a common commerce platform on cloud targeted at the large unorganized retail segment comprising of “Kiranas/ Kades”, Pharmacies and other consumer facing retail businesses in developing markets. It is built to enhance the retailers’ business through faster Sales Growth, better Financial Capabilities and improved Efficiency across the value chain.
Ava AG, founded in 2014 and headquartered in Zurich, Switzerland, specializes in women's health by developing the Ava bracelet, a wearable sensor device designed for nighttime use. This bracelet measures various physiological parameters to accurately predict a woman's fertile window and ovulation. The information gathered by the bracelet is accessible through a complementary mobile application, enabling users to gain insights into their reproductive health. Ava is committed to empowering women by providing them with the tools necessary to make informed decisions regarding their health and well-being. The company also maintains an office in Hong Kong to support its operations.
Rheon Medical SA develops adjustable glaucoma drainage systems. It also offers eyeWatch, an adjustable drainage device for treating glaucoma and eyePlate, a silicone drainage plate that connects outlet of eyeWatch device and allow the drainage of aqueous humor through the filtration of bleb forming. The company was founded in 2010 and is based in Lausanne, Switzerland.
Abionic SA, based in Lausanne, Switzerland, specializes in advanced diagnostic solutions leveraging nanotechnology. Founded in 2010 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), the company has developed the abioSCOPE platform, which enables rapid testing of patients using just a single drop of blood. This platform includes a reader for testing nano fluidic sensors and a mobile application for data management. Abionic's products are primarily utilized in clinical laboratories and point-of-care settings, focusing on improving medical diagnosis in areas such as allergy and sepsis detection. The company aims to establish itself as a key player in personalized medicine, particularly in allergy profiling. Abionic is certified under ISO 9001/13485, ensuring that its in vitro diagnostic devices meet stringent quality and regulatory requirements. The company is privately owned and receives support from EPFL, the Canton of Vaud, and Venturelab, reflecting its commitment to innovation in the healthcare sector.
Augurix SA design, develops, and markets diagnostics devices to facilitate early diagnosis and confirmation of gastro-intestinal diseases. It offers Simtomax, an accurate test that helps medical professionals in screening Celiac Disease at the point of care from whole blood, serum, plasma, or saliva. The company’s Simtomax is used in physician practices, pharmacies and screening venues, and laboratories. It sells its product through distributors in Switzerland and internationally. The company was founded in 2004 and is based in Monthey, Switzerland.
DistalMotion Sàrl, founded in 2012 and headquartered in Lausanne, Switzerland, specializes in developing medical devices for minimally invasive surgeries. The company focuses on creating surgical robotic technology that simplifies surgical processes, specifically in dissection and suturing. Its innovative robotic device enhances laparoscopic procedures in the abdominal cavity, allowing healthcare professionals to deliver improved patient care. By bridging the gap between surgical robotics and traditional laparoscopy, DistalMotion aims to transform the landscape of minimally invasive surgery.
Abionic SA, based in Lausanne, Switzerland, specializes in advanced diagnostic solutions leveraging nanotechnology. Founded in 2010 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), the company has developed the abioSCOPE platform, which enables rapid testing of patients using just a single drop of blood. This platform includes a reader for testing nano fluidic sensors and a mobile application for data management. Abionic's products are primarily utilized in clinical laboratories and point-of-care settings, focusing on improving medical diagnosis in areas such as allergy and sepsis detection. The company aims to establish itself as a key player in personalized medicine, particularly in allergy profiling. Abionic is certified under ISO 9001/13485, ensuring that its in vitro diagnostic devices meet stringent quality and regulatory requirements. The company is privately owned and receives support from EPFL, the Canton of Vaud, and Venturelab, reflecting its commitment to innovation in the healthcare sector.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies.
Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label. They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collecting insightful analytics. Improving your workflow is their top priority. Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
Viroblock SA is a healthcare company, engages in the development and marketing of antiviral products. It offers respiratory FFP2 mask with a mechanism of action against enveloped viruses, including human and avian influenzas, the hepatitis B and C viruses, and the AIDS virus. Its products and technologies have various prophylactic and therapeutic applications. Viroblock SA was founded in 2005 and is based in Geneva, Switzerland.
Sensimed AG is a medical devices company based in Lausanne, Switzerland, established in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for healthcare applications. Its flagship product, SENSIMED Triggerfish, is a single-use, soft hydrophilic contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The system includes various components such as disposable sensors, an adhesive antenna for data transmission, a battery-powered recorder, and software for data analysis. Sensimed aims to enhance clinical understanding of individual patient data by centralizing it in a registry, which allows for ongoing analysis to identify pathological patterns, personalize treatment, and evaluate treatment efficacy. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas.